Cadmium, Iron Deficiency Anemia and Hypophosphatemic Osteomalacia Due to Intravenous Iron Supplementation

1. Introduction

Iron deficiency anemia (IDA) is defined based on the levels of blood hemoglobin and the indicators of body iron content, like serum ferritin, free erythrocyte protoporphyrin and a transferrin saturation index [1,2,3,4,5]. Ferritin is an iron storage protein, as such, its concentration in the serum below 20 and 30 µg/L are indicative of body iron store depletion, and a low body iron store status, respectively [2,6]. However, because of the rising serum ferritin levels in chronic inflammatory conditions, soluble transferrin receptors (sTfR), and the sTfR–ferritin index have been employed for an accurate IDA assessment [2,6].

Based on blood hemoglobin levels below 12.0 g/dL in women and 13.0 g/dL in men, the 2021 global prevalence of anemia across all ages was 24.3% [7,8]. The predominant cause of anemia is iron deficiency, followed by hemoglobinopathies, hemolysis and chronic disease. IDA is a significant problem, especially among children (1-4 years), women of childbearing age, pregnant women [9,10,11], and people with chronic diseases, chronic kidney disease (CKD) included [6,12,13]. Moreover, IDA is a known risk factor for osteoporosis [14,15], while a high risk of bone fracture has been linked to low blood hemoglobin levels in men [16]. In a comprehensive review, Lichtler and Cowley have presented evidence connecting the prevalence of IDA and anemia with environmental exposure to cadmium (Cd), lead (Pb) and indoor and ambient air pollution, and fluoride [17].

Oral and intravenous iron supplementation have been in current use for IDA treatment and management [18,19,20]. Intravenous iron administration is used to bypass the gastrointestinal tract because of the low absorption rate of oral iron and its side effects. Iron infusion therapy increased hemoglobin concentrations more efficiently than oral iron in CKD patients, and resulted in higher hemoglobin and ferritin levels in pregnant women, compared with oral iron [10,11,12,13].

Concerningly, hypophosphatemic osteomalacia occurred in a particularly high frequency (50%) of patients who received intravenous iron therapy using ferric carboxymaltose preparation [19,20]. FGF23, a bone derived hormone, has been implicated; specifically, ferric carboxymaltose may inhibit the cleavage of FGF23, leading to an abrupt rise of active, intact FGF23 (iFGF23) [19,20]. Notably, iron deficiency per se can affect both synthesis and degradation of FGF23 from which iFGF23 and cleaved C-terminal FGF23 [(Cter)-FGF23] peptides are generated [21], and a Cter-FGF23 fragment has been linked to iron homeostasis independent of an effect of iFGF23 on renal phosphate reabsorption [22]. Moreover, other intravenous iron formulations also resulted in hypophosphatemic osteomalacia although in low frequencies (4-5%).

Hypophosphatemic osteomalacia due to chronic exposure to a high-dose Cd (>100 µg/day), experienced by itai-itai disease is now rare; however, the evidence connecting iron deficiency with environmental Cd exposure [17] together with hypophosphatemia osteomalacia in iron infusion therapy [19,20] has prompted us to the present work. Effects of Cd on intestinal absorption of iron leading to iron deficiency and are highlighted along with effects of IDA on Cd absorption and body burden of Cd. We discuss the potential role for Cd in the context of the adverse bone outcomes of iron infusion therapy. Additionally, we provide insight into effects of Cd on cellular stress response mechanisms involving heme oxygenase-1 (HO-1)/bilirubin axis. The two-hit hypothesis of Cd-induced cytotoxicity is presented.

2. Absorption and Accumulation of Cd in the Human Body

In this section, the intestinal absorption of Cd is discussed along with the use of blood Cd and urinary Cd as indicators of exposure to the metal. Effects of Cd on iron assimilation and a reduced cellular iron uptake revealed in recent long-term feeding trials are highlighted. Special emphasis is given to increased Cd absorption and Cd body burden in those with low body iron status.

2.1. Cd Exposure Route and Bone Outcome

Cd is present as a contaminant in virtually all food types, especially staple foods; inevitably, normal diets have become a common route of exposure [23,24,25]. Additional Cd exposure routes are tobacco smoke and airborne particle pollution, a concern especially among urban populations [26,27,28,29]. An exposure to a Cd dose between 10 and 15 µg/day may increase risk of osteoporosis [30,31,32].

In high doses; daily exposure to Cd at 100 µg or a life-time exposure of 1 g can cause itai-itai disease [33,34], where osteomalacia was observed in the presence of markedly reduced proximal tubular reabsorption of various filtered substances, phosphate included [35,36,37,38]. The manifestations of severe Cd poisoning were replicated using ovariectomized cynomolgus monkeys [38]. In a study using osteoblast-like cells, Kido et al. found that Cd increased expression of fibroblast growth factor 23 (FGF23), the regulator of vitamin D and phosphate homeostasis [40]. In a study by Aranami et al, a reduction in kidney tubular phosphate reabsorption in Cd-intoxicated mice was found to be mediated by FGF23 [41].

2.2. Intestinal Absorption of Cd

All living organisms cannot generate nor destroy any metal, and consequently, specialized metal transport proteins and pathways have been evolved to acquire all essential metals iron, zinc, manganese, calcium, and cobalt from exogenous sources (the diet) [42,43,44]. Even though Cd has no physiological role or nutritional value, its electronegativity and ionic radius are close to zinc, calcium, and iron; consequently, it is absorbed by the enterocytes. through the transport mechanisms and pathways for essential metals (Figure 1).

Examples of metal transport proteins responsible for absorption of Cd in an ionic form (Cd²⁺) are those for calcium (TRPV6), zinc (ZIP14), iron (DMT1) [45,46,47,48,49,50]. Cd in complexes with metallothionein (MT) and the plant metal binding ligand phytochelatin (PC) are absorbed through transcytosis [51] and endocytosis mediated by human neutrophil gelatinase-associated lipocalin (hNGAL) [52,53].

The rate of individual metal assimilation is regulated by the specificity and the enterocyte levels of individuals transporters expressed by enterocytes. Such regulatory modes are pivotal to prevent metal deficiency as well as metal overload. Two metal efflux transporters have been found to display an absolute specificity; ferroportin1 (FNP1) has an absolute specificity for iron (Fe2+) [54,55], whereas ZnT1 is for the extrusion of only Zn (2+) [56]. These suggests that Cd is retained within the cells due to no exit route; a long residence time of Cd in cells.

The transport protein for iron or zinc only means also that the absorption rate of Cd exceeds that of iron or zinc, given that Cd enters the enterocytes through multiple routes. At any given time, the whole blood Cd level is indicative of recent exposure because the average lifespan of erythrocytes is 120 days. The biological half-life of blood Cd ranged between 75 and 128 days [57]. The half-life of Cd in the body varied from 7.4 to 30 years; the lower the bodily burden, the longer the half-life of Cd [58,59,60].

2.3. Urinary Cd Is Indicative of Body Burden and Toxicity at the Present Time

Acquired Cd accumulates mostly within the kidney tubular cells, where its levels increase through to the age of 50 years but decline thereafter due to its release into the urine as the injured tubular cells die for any reason [61]. Thus, urinary Cd reflects its nephrotoxicity at the present time [61]. A study of environmentally exposed Chinese subjects aged 2.8 to 86.8 years (n = 1235) showed that Cd excretion levels increased with age, peaking at 50 years in non-smoking women and 60 years in non-smoking men [62].

Based on a direct relationship between urinary Cd and the accumulation of Cd in the kidney cortex, urinary Cd is an indicator of the body burden of the metal [63,64,65,66]. Using data from kidney transplant donors, urinary Cd of 0.42 μg/g cr corresponded to kidney Cd of 25 μg/g wet tissue weight [65]; urinary Cd 0.34 μg/g cr in women corresponded to kidney Cd of 17.1 μg/g, and urinary Cd of 0.23 μg/g cr in men corresponded to kidney Cd of 12.5 μg/g [66].

2.4. Iron Deficiency Induced by Cd: Breakthrough Studies

Using a long-term feeing strategy, Tokumoto et al. have shown, for the first time, an effect of Cd on iron absorption, leading to iron deficiency in Cd toxicity targets [67]. A significant reduction in hepatic iron content was observed in groups of female C57BL/6J mice given a diet containing 300 ppm Cd for 12, 15, 19 and 21 months [67]. Such a decrease in hepatic iron content was attributable to Cd-induced suppression of duodenal expression of the HCP1 and Cybrd1 genes, encoding the influx transporters for heme iron and non-heme iron, respectively. As Figure 1 presents, CYBRD1 is required to reduce Fe3+ to absorbable form, Fe2+. Interestingly, Cd did not seem to influence the duodenal expression of the iron efflux transporters [67]. The conditions may favor Cd absorption. In summary, Cd reduced duodenal absorption of both heme iron and non-heme iron, leading to a decrease in hepatic iron storage (ferritin), indicative of the low body iron store status.

In another breakthrough study where Sprague Dawley male rats were given Cd in drinking water at 0, 50, 75 mg/L CdCl2 for 1 and 6 months, Zhang et al. observed a decrease in iron content in the proximal tubular cells of the kidneys [68]. They found, like the study by Tokumoto et al. that Cd affected the duodenal expression of the genes encoding specialized transport proteins for metals. Specifically, Cd suppressed the expression of SLC11A2 gene and SLC40A1 genes, encoding divalent metal transporter1 (DMT1) and ferroportin1 (FPN1). Additionally, Cd lowered the expression levels of various metal transporters by the kidney tubular cells which included SLC11A2 (DMT1), CUBN (cubilin), LRP2 (megalin), SLC39A14 (ZIP14), and SLC39A8 (ZIP8). These data suggest that a long-term Cd exposure may induce iron insufficient state in tubular cells through decreasing the duodenal absorption of iron, systemic transport, and uptake of iron by tubular cells.

The above findings lend support to a connection between low environmental exposure to Cd and a high prevalence of iron deficiency, especially in vulnerable subpopulation groups. They also prompted us to explore potential impact of Cd on undesirable bone outcomes of intravenous iron supplementation, through inducing iron deficiency (Section 3).

3. Undesirable Bone Outcomes in Iron Infusion Therapy

Speculatively, hypophosphatemic osteomalacia was linked to the use of ferric carboxymaltose preparation. Nonetheless, such bone outcome occurred also with other iron formulations [19,20], which may indicate potential involvement of different pathogenic factors. Recent research studies show that inflammation, anemia, and dysregulated iron homeostasis (overload/deficiency) can impact FGF23 synthesis and its cleavage to iFGF23 and Cter-FGF23 [21,22]. Moreover, the Cter-FGF23 fragment may have biological role distinct from iFGF-23 [21,22].

To reveal similarities/differences in pathological features, we review reported cases of bone complications following iron infusion therapy. Also, we review a proven case of hypophosphatemic osteomalacia in an Indian jewellery male worker, exposed to a high dose of Cd in fumes [69]. His blood Cd level was 6-time higher than an occupational exposure limit of 5 µg/L [69].

3.1. Hypophosphatemic Osteomalacia

Samões et al. reported a case of a 70-year-old man who had Rendu–Osler–Weber disease and developed hypophosphatemic osteomalacia as a complication of frequent infusions of ferric carboxymaltose for more than 10 years [70]. Vilaca et al. have published a systematic review, in which the authors included 28 case reports (30 patients, aged 28-80 years) of osteomalacia developed as a complication of intravenous iron infusions [71]. Initially, all 30 individuals had IDA from gastrointestinal diseases or gynecological bleeding. These subjects underwent treatment with repeated intravenous iron infusions using various iron preparations (saccharated ferric oxide, iron polymaltose, and ferric carboxymaltose), which led to osteomalacia marked by musculoskeletal pain, fractures, and pseudofractures. Most cases had rising plasma iFGF23 levels; nonetheless, C-terminal FGF23 (Cter-FGF23) levels were also elevated in some cases, along with hypophosphatemia and increased plasma FGF23 levels. Clinical picture involved bone pain and onset of fractures. Additionally, some of the included subjects had comorbidities such as Crohn disease, or were treated with glucocorticoids [72], both of which may significantly influence bone quality [73,74].

Establishing a link between intravenous iron supplementation and the onset of osteomalacia is a challenging task. Namely, the majority or all of these individuals had IDA prior to iron infusions, and IDA itself may damage bone [75,76,77,78]. Thus, the effects of IDA and iron infusion were indistinguishable. Moreover, individuals with IDA may have had elevated blood Cd concentrations [79,80,81], which is toxic to bones [82]. It would not be possible to determine whether osteomalacia is a consequence of IDA, Cd toxicity, or a transient iron overload.

A case report on Cd-induced hypophosphatemic osteomalacia has recently been published. Namely, the authors reported a case of a man in his 40s who complained of lower-back pain. Using X-ray imaging, pseudofractures were observed [83]. His blood Cd level of 30 µg/L was sixfold above an occupational exposure limit of 5.0 µg/L. He also had hypochromic microcytic anemia and elevated cFGF23, and was ultimately diagnosed with hypophosphatemic osteomalacia due to severe Cd toxicity [83].

Comparative overview of the main characteristics of cases of the reported iron infusion–mediated osteomalacia and cases of Cd-mediated osteomalacia shows that the two conditions share all major characteristics, namely presence of IDA, increased plasma FGF23 levels, hypophosphatemia, and bone pain. Unfortunately, Cd exposure levels were not measured in the cases where iron was found “guilty” for the onset of hypophosphatemic osteomalacia; measuring of Cd exposure levels in those cases would be helpful to clarify whether Cd contributed or caused osteomalacia.

Changing therapy from intravenous to oral administration of iron brings improvement in those individuals treated with intravenous iron supplementation [71]. This improvement can be easily explained since Cd and iron share the same intestinal metal transporters and pathways (Section 2.2). DMT1, ZIP8, and ZIP14 metal transporters are expressed in the duodenum [84], and they are likely responsible for assimilation of iron, zinc, and Cd [85,86]. This further suggests that iron and Cd would compete for same metal transport proteins; consequently, less Cd would enter the circulation in response to oral iron supplementation.

Interestingly, although it was speculated that plasma FGF23 levels would drop after the cessation of intravenous iron supplementation, Klein et al. reported that FGF23 remained elevated for months after the last infusion [87]. This may indicate involvement of factors influencing FGF23 synthesis and cleavage. This should not suggest hypophosphatemic osteomalacia as alone consequence of a low-dose Cd exposure. Rather, the contributions of environmental Cd, iron deficiency for any cause, and iron infusion cannot be separated, and previous studies have considered only iron infusion as the sole cause. Our working hypothesis to explain involvement of Cd through iron deficiency is presented in Figure 2.

Osteoblasts can easily uptake circulating Cd when it is bound to transferrin [88] and transferrin receptor 1 (TfR1) is expressed on the osteoblast surface [89]. The expression of Trf1 is upregulated by IDA due to the accumulation of hypoxia-inducible factors (HIFs) [90]. Following its entry into osteoblasts, Cd promotes the secretion of iFGF23, which then reduces tubular reabsorption of phosphate, demonstrated previously [41,42]. IDA increased also the abundance of TfR1 on the cell surface [91,92], resulting in an enhanced uptake of Cd since, as discussed, Cd is bound to transferrin [92]. In effect, osteoblasts could take up and accumulate Cd for a prolonged period, and Cd promotes excessive ROS (Section 4), leading to some extent cell damage. When there is suddenly a significant amount of iron in circulation, osteoblasts uptake it as well. Results of an in vivo study demonstrated that Cd toxicity is potentiated in the presence of iron [93]. It would not be possible to ascertain whether those individuals would develop osteomalacia after iron infusion if they were minimally exposed to Cd. However, this could be shown if chelation therapy were applied before iron infusion.

3.2. Fracture Risk

Anemia and iron deficiency have been linked to risk of fractures and postoperative complications after hip fracture [94,95,96,97]. Lee et al. analyzed fracture risk in a large retrospective study that recruited over 70,000 individuals, of which 10,568 (15.1%) had anemia (not classified) [97]. They observed that both men and women with anemia had an increased risk of sustaining vertebral and femoral fractures; moreover, a negative correlation was found between hemoglobin levels and fracture risk for both sites examined. A higher fracture risk was independently associated with current smoking status in another study [97].

In a study from Sweden, an increased risk of incident osteoporosis-related fractures was observed in those who never smoked; the risk of fracture rose 58% per μg/L increase in blood Cd. This result was obtained after adjustment for age, sex, BMI, physical activity, and fiber consumption [98]. Blood Cd as little as 0.31 µg/L appeared to be sufficient to increase fracture risk by 21%, compared to blood Cd <0.15 μg/L [98]

A Swedish prospective study conducted on 1005 men (66 with anemia) who participated in the Osteoporotic Fractures in Men (MrOS) study, evaluated whether anemia (not classified) could be associated with an increased fracture risk [92,99]. The median follow-up time in that study was 10.1 years, during which 346 participants sustained fractures. The hazard ratio for any fracture type was almost doubling, even after adjusting for age and hip bone mineral density (BMD). Of note, individuals with anemia had higher circulating levels of intact fibroblast growth factor 23 (iFGF23) independent of age, erythropoietin levels, and eGFR) [99].

Similarly, Valderrábano et al. examined the association between anemia and fracture risk in 3632 aged men, 249 had anemia [100]. Their results showed that the presence of anemia increased the risk of any fracture type by 67%, while the risk for non-vertebral fractures was even slightly more pronounced [100].

A study from Norway examined whether anemia could predict non-vertebral fractures [101]. This study included 5286 individuals (2511 men and 2775 women), aged 55 to 74 years. Like the Swedish men study [100], Jørgensen and colleagues found that men with anemia had a twofold higher risk of non-vertebral fractures compared with men with desirable hemoglobin levels. However, after adjusting for various variables such as lipid profiles, forearm BMD, hand grip strength, BMI, smoking status, and creatinine levels, the significant effect of anemia on fracture risk was lost for women, but remained significant for men [101].

Teng and colleagues conducted a meta-analysis of data from seven original articles [95]. They found that the pooled relative risk for any fracture type in individuals with anemia was 1.26. After stratifying the risk by location, they reported a higher fracture risk for hip fractures than for vertebral fractures in individuals with anemia. Additionally, men had a greater fracture risk than women, although the presence of anemia led to increased fracture risk in both sexes and for both examined sites [95]. Results from another study from the US, which included 160,080 women, indicated an increased risk of spine, hip, and all-type fractures, with hip fracture risk being particularly high in individuals with anemia (hazard ratio 1.81) [102].

3.3. IDA

Most studies have shown that IDA and iron deficiency had direct effects on bone quality [76,77]. Pioneering work in the field of IDA-induced bone alterations revealed that rats fed with an iron-deficient diet had lower bone mineral density in the femur and spine and worse mechanical properties compared with rats with adequate iron intake [77].

In an in vivo study where rats were fed a low-iron diet for 5 weeks, the low-iron-intake group had lower whole-body and femur DXA scores and deteriorated lumbar microarchitecture. This deterioration was reflected in lower bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N), along with a higher structure model index and trabecular separation. In another study using Wistar rats fed with an iron-deficient diet, Diaz-Castro et al. observed decreasing levels of procollagen type I N-terminal propeptide, coupled with rising serum parathormone (PTH), indicative of bone resorption [76].

3.4. Other Potential Contributors

Osteomalacia due to vitamin D deficiency is characterized by altered mineralization of newly formed osteoid. Chwalba et al. divided 140 children into two groups based on whether their blood Cd levels were above or below the median (0.27 µg/L), and reported that children with blood Cd above median had 23% lower serum vitamin D levels [103]. There is some evidence that Cd could disrupt the final hydroxylation reaction of provitamin D in the kidneys [104,105].

In summary, IDA impacted unequivocally, bone quality. This means that IDA-induced adverse bone effects may also have contributed to fracture, especially in the cases where osteomalacia followed an iron infusion treatment. Namely, Vilaca et al. reported that 22 individuals sustained fractures [71]. Since IDA causes bone alteration and it is speculated that iron infusion can also damage bones, it is difficult distinguish whether the fractures occurred due to IDA, iron infusion, or a combination of these. Moreover, ID can raise the circulating iFGF23 concentrations, as confirmed in studies in vivo [106,107,108] and humans [109,110]. The serum iFGF23 concentrations inversely correlated with serum Fe levels [110]. Evidence that anemia, iron deficiency and inflammation, through HIF1α and erythropoietin, upregulate the FGF23 gene is increasingly reported.

4. Bone Toxicity Mechanism of Cd

In this section, we summarize results of empirical studies supporting epidemiological/clinical data discussed in Section 3. A two-hit hypothesis is presented to explain the molecular basis of Cd cytotoxicity involving stress response and defense against bone cell death through ferroptosis; an iron-dependent form of regulated cell death induced by lipid peroxidation.

4.1. Experimental Data

Using in vitro experiments, Cd-intoxicated osteoblasts were less viable and they secreted less alkaline phosphatase [111]. Another study provided evidence that Cd stimulated bone resorption by upregulating RANK expression [112]. Interestingly, Wan et al. demonstrated that Cd per se may affect bone mineralization [113]. Namely, they investigated effects of Cd on human bone marrow mesenchymal stem cells in vitro and obtained that Cd-exposed cells at the doses of 2.5 and 5 μM CdCl₂ lacked intracellular calcification nodules in terms of quantity and volume detected by alizarin red staining [113,115]. In the second part of their research, Wan et al. showed a negative relationship between bone morphogenetic protein 4 and urinary Cd levels [114]. Bone morphogenetic protein 4 has a significant role in bone mineralization [115].

Liu et al. investigated mechanisms by which Cd induced osteoblast death [118], where they employed osteoblasts derived from Sprague-Dawley rat fetuses treated with 0, 1, 2, and 5 μM Cd. They observed changes in osteoblast nucleus morphology and the upregulation of Bax but the downregulation of Bcl-2 (which has antiapoptotic activity) [116]. In another in vitro study utilizing MC-3T3-E1 cells, exposure to CdCl₂ at 0–20 μM decreased cell viability, and promoted osteoblast apoptosis, which resulted from a decreased Bcl-2 level and accumulation of Bax mRNA and protein, and interfered with osteoblast formation by decreasing the expression of RANKL [117].

In additional to induction of FGF23 expression in the osteoblast-like cells [40], a series of experimental studies have ascertained that Cd effects on osteoclasts and osteoblasts via multiple mechanisms, including RANKL-RANK axis [116,117]. Ran et al. demonstrated that SIRT1/PGC-1α/P53Lys382 signaling pathway could mediate osteoporosis due to Cd, while noting that bones from patients with osteoporosis had an elevated Cd level [118].

In summary, Cd promotes bone resorption by causing premature death (ferroptosis) of osteoblasts, while increasing the formation of osteoclasts. These findings are in line with current views on the significance of ferroptosis in normal bone health and pathogenesis of Cd-induced osteoporosis [119,120].

4.2. Hypothetical Two-Hit Mechanism of the Cytotoxiicty of Cd

Potential contribution of iron-dependent cell death (ferroptosis) in pathogenesis of osteomalacia in itai-itai disease patients was first evident from a study by Noda et al. who examined 23 autopsy cases of itai-itai disease and 18 cases of sudden death as controls [121]. Using histochemical staining and x-ray microanalysis, iron was found in approximately half of mineralization fronts, and the bone content of Cd was 4.5-time higher in patients with itai-itai disease, compared to control subjects [121]. Iron presence at mineralization fronts was also found in rats and monkeys treated with Cd [39,122].

Given a unique role of heme oxygenase-1 (HO-1) in cellular stress response and defense against oxidative damage [123,124], we hypothesize that through excessive ROS and damage to mitochondria, Cd causes a release iron from heme, ultimately leading to cell death (ferroptosis) (Figure 3).

It is important to note; firstly that Cd at very low concentrations can cause a massive increase in HO-1 protein and catalytic activity because it activates the HO-1 gene through cadmium response element (CdRE) in additional to antioxidant response element (ARE) [124,125,126,127]. Secondly, the increase in HO-1 enzyme activity by Cd is not coupled with bilirubin synthesis [128,129]. In effect, Cd increases intracellular levels of Fe2+, while depriving cells of the ability to protect cells against lipid peroxidation and ferroptosis ensues. Expression of ZnT1 by Cd can lead to cellular zinc depletion because ZnT1 has an absolute specificity for zinc as is FNT1, a cell exit route for iron only. Experimental studies show that zinc reduced osteoclast activities and increased the number of osteoblasts [130,131] and that oxidative stress due to zinc deficiency promoted RANKL expression in rat bones [133].

Cytoprotective effects of certain phytochemicals and medicinal plants through HO-1/bilirubin axis activation are being explored using the ARE reporter assays [124], which could be used to mitigate effects of Cd on bone [133,134].

5. Conclusions

A combined effect of iron deficiency and Cd bone toxicity may explain partially bone complications of intravenous iron supplementation therapy. The synthesis and cleavage of the bone-derived FGF23 forming intact (iFGF23) and Cter-FGF23 peptide fragments are affected by IDA and iron deficiency. The Cter-FGF23 fragment has been linked to iron homeostasis independent of iFGF23 role in renal phosphate reabsorption. In experimental studies, Cd increased FGF23 expression by osteoblast-like cells and suppressed FGF23 cleavage leading to a rise of serum FGF23, which, in turn, mediated an effect of Cd on tubular phosphate reabsorption. Moreover, Cd may interfere with vitamin D metabolism and bone mineralization.

While a rising Cd body burden might be a contributing factor, IDA may, in part, account for an increased prevalence of fractures due to Cd because IDA increases Cd absorption and accumulation in bones; bone tissues from patients with osteoporosis had higher Cd levels, compared to controls. Unfortunately, Cd exposure was not quantified in any report relating intravenous iron therapy to hypophosphatemic osteomalacia; noting, however that iron deficiency and Cd could raise plasma iFGF23 levels independently. Current evidence suggests distinct role for Cter-FGF23 fragment in the regulation of iron homeostasis, while suppressing erythropoietin synthesis in kidneys by FGF23 contributes further to anemia.

Evidence that environmental Cd increases the prevalence of iron deficiency and IDA in the general population calls for an effort to address a range of environmental exposures in future iron supplementation programs. The ability of Cd to reduce iron absorption and iron deficiency has recently been demonstrated using long-term feeding studies. Previous short-term dosing experiments failed to reveal such effects of Cd on iron absorption that can lead to iron deficiency if exposure to the metal continues; a likely scenario because Cd exposure occurs through a normal diet.

In theory, Cd can enter any cell in the body using metal transport proteins, receptors and pathways for iron and zinc (e.g., DMT1, ZIP14, ZIP8, TfR). Through CdRE and MARE/NrF₂, Cd induces a massive increase in HO-1 enzyme activity resulting in a release of iron (Fe2+) from heme. However, by the mechanism remains unknown, the upregulation of HO-1 in response to Cd is not coupled with the generation of bilirubin, a potent lipid peroxidation chain breaker; consequently, extensive cellular oxidative damage and cell death (ferroptosis) may ensue.

At very low concentrations, Cd induces the expression of ZnT1, a highly specific zinc efflux transporter; consequently, zinc deficiency is inevitable because zinc is extruded from cells by ZnT1 while Cd is retained within cells. Like the bilirubin synthesis hit by Cd, cellular zinc deficiency is a universal cytotoxic mechanism of Cd.

Avoidance of foods containing high levels of Cd and smoking cessation are pivotal as is the maintenance of optimal body contents of iron and zinc. Dietary antioxidants provide a complementary preventive measure.